{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-006124","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2025-01-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.016435+00:00","generated_at":"2026-05-28T02:11:08.267121+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Kymera reports $850M cash, outlines 2025 pipeline milestones for KT-621, KT-295, KT-474","bullets":["Preliminary cash ~$850M as of Dec 31, 2024; runway into mid-2027.","KT-621 Phase 1 healthy volunteer data expected Q2 2025; Phase 1b AD starts Q2 2025 with data Q4 2025.","KT-295 (TYK2) IND/Phase 1 start Q2 2025; data expected late 2025.","KT-474 (IRAK4) Phase 2b dose-ranging in HS and AD ongoing, completion expected 1H26 and mid-2026.","Novel oral immunology program (first-in-class) to be disclosed 1H2025; clinical testing expected early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-006124","json":"https://secwatch.observer/filing/0001193125-25-006124.json","markdown":"https://secwatch.observer/filing/0001193125-25-006124.md","text":"https://secwatch.observer/filing/0001193125-25-006124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/0001193125-25-006124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312525006124/d918233d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T02:11:08.267121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}